NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.

On May 25, 2017, NeoGenomics, Inc., a Nevada corporation (the
Company), held an annual meeting of its stockholders.At the
annual meeting, 73,446,421 shares of the Companys common stock,
par value $0.001 per share, and all 6,600,000 shares of the
Companys Series A redeemable convertible preferred stock, par
value $0.001 per share (together with the common stock, Voting
Stock), were present or represented by proxy at the meeting,
representing approximately 93% of the outstanding Voting Stock as
of April 7, 2017, the record date for the annual meeting. At the
annual meeting, four proposals were submitted for a vote of the
Companys stockholders and the related results are as follows:

(1)Proposal No. 1: The election of Douglas M. VanOort, Steven C.
Jones, Kevin C. Johnson, Raymond R. Hipp, William J. Robison,
Bruce K. Crowther, Lynn A. Tetrault, Alison L. Hannah and Kieran
P. Murphy to serve as members of the Board of Directors until the
next succeeding annual meeting of stockholders or until his or
her successor has been duly elected and qualified.The
stockholders elected the nine directors by the following votes:

(2) Proposal No. 2: The approval of the amendment of the amended
and restated equity incentive plan, as identified in the proxy
statement for the annual meeting.The stockholders approved the
proposal by the following vote:

(3) Proposal No. 3: The approval of the amendment of the amended
of the employee stock purchase plan, as identified in the proxy
statement for the annual meeting.The stockholders approved the
proposal by the following vote:

(4) Proposal No. 4: The ratification of the independent
registered public accountant.The stockholders approved the
proposal by the following vote:

Item 8.01.Other Matters.

The investor presentation attached hereto as Exhibit 99.1 was
presented to the Companys stockholders at the annual meeting.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

99.1 Annual Shareholder Meeting Presentation dated May 25, 2017

About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

NEOGENOMICS, INC. (NASDAQ:NEO) Recent Trading Information

NEOGENOMICS, INC. (NASDAQ:NEO) closed its last trading session down -0.04 at 7.34 with 171,836 shares trading hands.